Nicotinamide phosphoribosyltransferase/sirtuin 1 pathway is involved in human immunodeficiency virus type 1 Tat-mediated long terminal repeat transactivation

Journal of Cellular Biochemistry

Volumn 110, Issue 6, 2010, Pages 1464-1470

  Zhang, Hong Sheng ^a   Sang, Wei Wei ^a   Wang, Yu Ou ^a   Liu, Wei ^a  

^a BEIJING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

HIV 1; LTR transactivation; Nampt; SIRT1; Tat

Indexed keywords

MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESVERATROL; SIRTUIN 1; TRANSACTIVATOR PROTEIN;

ARTICLE; ENZYME ACTIVATION; ENZYME ACTIVITY; HELA CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTIGENS, CD4; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BETA-GALACTOSIDASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HIV LONG TERMINAL REPEAT; HUMANS; IMMUNOBLOTTING; NAD; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SIRTUIN 1; STILBENES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTIONAL ACTIVATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77955489675     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22704     Document Type: Article

References (35)

1. Baba M. 2006. Recent status of HIV-1 gene expression inhibitors. Antiviral Res 71:301-306.
2. Blazek D, Peterlin BM. 2008. Tat-SIRT1 tango. Mol Cell 29:539-540.
3. Borradaile NM, Pickering JG. 2009. NAD(+), sirtuins, and cardiovascular disease. Curr Pharm Des 15:110-117.
4. Garten A, Petzold S, Körner A, Imai S, Kiess W. 2009. Nampt: Linking NAD biology, metabolism and cancer. Trends Endocrinol Metab 20:130-138.
5. Grubisha O, Smith BC, Denu JM. 2005. Small molecule regulation of Sir2 protein deacetylases. FEBS J 272:4607-4616.
6. Haigis MC, Guarente LP. 2006. Mammalian sirtuins - Emerging roles in physiology, aging, and calorie restriction. Genes Dev 20:2913-2921.
7. Harrich D, McMillan N, Munoz L, Apolloni A, Meredith L. 2006. Will diverse Tat interactions lead to novel antiretroviral drug targets? Curr Drug Targets 7:1595-1606.
8. Imai S. 2009a. From heterochromatin islands to the NAD World: A hierarchical view of aging through the functions of mammalian Sirt1 and systemic NAD biosynthesis. Biochim Biophys Acta 1970:997-1004.
9. Imai S. 2009b. The NAD World: A new systemic regulatory network for metabolism and aging - Sirt1, systemic NAD biosynthesis, and their importance. Cell Biochem Biophys 53:65-74.
10. Imai S. 2009c. Nicotinamide phosphoribosyltransferase (Nampt): A link between NAD biology, metabolism, and diseases. Curr Pharm Des 15:20-28.
11. Imai S, Kiess W. 2009. Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes. Front Biosci 14:2983-2995.
12. Karn J. . Tackling Tat J Mol Biol 293:235-254.
13. Kimpton J, Emerman M. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 66:2232-2239.
14. Kwon HS, Brent MM, Getachew R, Jayakumar P, Chen LF, Schnolzer M, McBurney MW, Marmorstein R, Greene WC, Ott M. 2008. Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe 3:158-167.
15. Michan S, Sinclair D. 2007. Sirtuins in mammals: Insights into their biological function. Biochem J 404:1-13.
16. + salvage pathway by CLOCK-SIRT1. Science 324:654-657.
17. Ott M, Dorr A, Hetzer-Egger C, Kaehlcke K, Schnolzer M, Henklein P, Cole P, Zhou MM, Verdin E. 2004. Tat acetylation: A regulatory switch between early and late phases in HIV transcription elongation. Novartis Found Symp 259:182-193.
18. Pagans S, Pedal A, North BJ, Kaehlcke K, Marshall BL, Dorr A, Hetzer-Egger C, Henklein P, Frye R, McBurney MW, Hruby H, Jung M, Verdin E, Ott M. 2005. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol 3:e41.
19. Revollo JR, Grimm AA, Imai S. 2007. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 23:164-170.
20. Richter SN, Palu G. 2006. Inhibitors of HIV-1 Tat-mediated transactivation. Curr Med Chem 13:1305-1315.
21. Robinson R. 2007. A simple feedback resistor switch keeps latent HIV from awakening. PLoS Biol 5:e25.
22. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, Andris F. 2002. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 32:3225-3234.
23. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. 1994. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colonyenhancing factor. Mol Cell Biol 14:1431-1437.
24. Saunders LR, Verdin E. 2007. Sirtuins: Critical regulators at the crossroads between cancer and aging. Oncogene 26:5489-5504.
25. +)-sirtuin-1-dependent pathway. Nat Med 15:151-158.
26. Stevens M, De Clercq E, Balzarini J. 2006. The regulation of HIV-1 transcription: Molecular targets for chemotherapeutic intervention. Med Res Rev 26:595-625.
27. Sun Y, Huang YC, Xu QZ, Wang HP, Bai B, Sui JL, Zhou PK. 2006. HIV-1 Tat depresses DNA-PK(CS) expression and DNA repair, and sensitizes cells to ionizing radiation. Int J Radiat Oncol Biol Phys 65:842-850.
28. van Gool F, Gallí M, Gueydan C, Kruys V, Prevot PP, Bedalov A, Mostoslavsky R, Alt FW, De Smedt T, Leo O. 2009. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat Med 15:206-210.
29. van Lint C, Emiliani S, Ott M, Verdin E. 1996. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 15:1112-1120.
30. Xu WS, Parmigiani RB, Marks PA. 2007. Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene 26:5541-5552.
31. Yang XJ, Seto E. 2007. HATs and HDACs: From structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26:5310-5318.
32. Zhang HS, Wu MR. 2009. SIRT1 regulates Tat-induced HIV-1 transactivation through activating AMP-activated protein kinase. Virus Res 146:51-57.
33. + salvage pathway regulate SIRT1 activity at target gene promoters. J Biol Chem 284:20408-20417.
34. Zhang HS, Li HY, Zhou Y, Wu MR, Zhou HS. 2009a. Nrf2 is involved in inhibiting Tat-induced HIV-1 long terminal repeat transactivation. Free Radic Biol Med 47:261-268.
35. +-dependent SIRT1 activity. Life Sci 85:484-489.